Who Generates Higher Gross Profit? Bausch Health Companies Inc. or Ligand Pharmaceuticals Incorporated

Bausch Health's Gross Profit Dominates Over Ligand Pharmaceuticals

__timestampBausch Health Companies Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014600890000055402000
Thursday, January 1, 2015785380000066107000
Friday, January 1, 20167063000000103402000
Sunday, January 1, 20176176000000135736000
Monday, January 1, 20186029000000245116000
Tuesday, January 1, 20196251000000108935000
Wednesday, January 1, 20205778000000156000000
Friday, January 1, 20216040000000214957000
Saturday, January 1, 20225760000000143418000
Sunday, January 1, 2023619800000096265000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Bausch Health vs. Ligand Pharmaceuticals

In the competitive landscape of the pharmaceutical industry, gross profit is a key indicator of a company's financial health and operational efficiency. From 2014 to 2023, Bausch Health Companies Inc. consistently outperformed Ligand Pharmaceuticals Incorporated in terms of gross profit. Bausch Health's gross profit peaked in 2015, reaching nearly 8 billion, while Ligand's highest was in 2018, with a modest 245 million. Over the decade, Bausch Health's average gross profit was approximately 48 times greater than Ligand's. This stark contrast highlights Bausch Health's robust market presence and operational scale. Despite Ligand's growth, particularly in 2018, it remains a smaller player in comparison. Investors and industry analysts should consider these trends when evaluating the financial strategies and market positions of these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025